Have a feature idea you'd love to see implemented?
Let us know!
IMNM Immunome Inc
Price (delayed)
$11.59
Market cap
$696.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.69
Enterprise value
$533.08M
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are
Highlights
The revenue has soared by 63% YoY but it fell by 15% QoQ
Immunome's gross profit has surged by 63% YoY but it has decreased by 15% QoQ
IMNM's debt has surged by 105% since the previous quarter
Immunome's quick ratio has decreased by 31% QoQ
Key stats
What are the main financial stats of IMNM
Market
Valuations
Earnings
Shares outstanding
60.05M
Market cap
$696.03M
Enterprise value
$533.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.74
Price to sales (P/S)
64.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.43
Revenue
$10.78M
EBIT
-$262.59M
EBITDA
-$261.23M
Free cash flow
-$65.53M
Per share
Balance sheet
Liquidity
EPS
-$7.69
Free cash flow per share
-$1.09
Book value per share
$4.23
Revenue per share
$0.18
TBVPS
$4.94
Total assets
$296.22M
Total liabilities
$42.38M
Debt
$2.48M
Equity
$253.84M
Working capital
$244.38M
Debt to equity
0.01
Current ratio
7.12
Quick ratio
6.98
Net debt/EBITDA
0.62
Margins
Efficiency
Dividend
EBITDA margin
-2,422.4%
Gross margin
100%
Net margin
-2,435%
Operating margin
-2,518.5%
Return on assets
-122.5%
Return on equity
-157.9%
Return on invested capital
-858.8%
Return on capital employed
-102.4%
Return on sales
-2,435%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMNM stock price
How has the Immunome stock price performed over time
Intraday
-1.02%
1 week
-6.08%
1 month
-17.21%
1 year
34.61%
YTD
8.32%
QTD
-20.73%
Financial performance
How have Immunome's revenue and profit performed over time
Revenue
$10.78M
Gross profit
$10.78M
Operating income
-$271.59M
Net income
-$262.59M
Gross margin
100%
Net margin
-2,435%
The revenue has soared by 63% YoY but it fell by 15% QoQ
Immunome's gross profit has surged by 63% YoY but it has decreased by 15% QoQ
Immunome's operating margin has decreased by 35% from the previous quarter
IMNM's net margin is down by 33% since the previous quarter
Growth
What is Immunome's growth rate over time
Valuation
What is Immunome stock price valuation
P/E
N/A
P/B
2.74
P/S
64.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.43
The price to book (P/B) is 62% lower than the last 4 quarters average of 7.2
The equity has contracted by 11% from the previous quarter
The revenue has soared by 63% YoY but it fell by 15% QoQ
IMNM's price to sales (P/S) is 35% higher than its last 4 quarters average of 48.2
Efficiency
How efficient is Immunome business performance
The ROIC has soared by 95% from the previous quarter
The company's return on assets has shrunk by 65% YoY but it rose by 20% QoQ
IMNM's ROS is down by 33% QoQ
Immunome's ROE has increased by 28% from the previous quarter and by 7% YoY
Dividends
What is IMNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMNM.
Financial health
How did Immunome financials performed over time
Immunome's total liabilities has increased by 32% YoY and by 24% from the previous quarter
Immunome's quick ratio has decreased by 31% QoQ
IMNM's debt is 99% smaller than its equity
IMNM's debt has surged by 105% since the previous quarter
The equity has contracted by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.